Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn

Suven Pharmaceuticals will acquire a 56% stake in US-based NJ Bio Inc for USD 64.4 million. This acquisition aligns with Suven's goal of becoming a leading technology-driven CDMO, specializing in antibody-drug conjugates (ADCs). NJ Bio's expertise and client base will boost Suven's presence in the rapidly expanding ADC/XDC market.